Eagle Pharmaceuticals Inc.

43.73+1.35+3.19%Vol 113.61K1Y Perf -3.94%
Jun 27th, 2022 16:00 DELAYED
BID39.89 ASK54.31
Open42.75 Previous Close42.38
Pre-Market- After-Market43.73
 - -  - -%
Target Price
48.50 
Analyst Rating
Moderate Buy 2.33
Potential %
10.91 
Finscreener Ranking
★★     46.23
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.76
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     57.99
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
15.78 
Earnings Rating
Strong Sell
Market Cap577.85M 
Earnings Date
8th Aug 2022
Alpha-0.01 Standard Deviation0.11
Beta0.67 

Today's Price Range

42.7144.74

52W Range

41.0158.25

5 Year PE Ratio Range

9.1067.00

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
2.60%
1 Month
-9.93%
3 Months
-14.00%
6 Months
-17.23%
1 Year
-3.94%
3 Years
-21.46%
5 Years
-45.74%
10 Years
-

TickerPriceChg.Chg.%
EGRX43.731.35003.19
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
2.00
2.40
0.01
0.13
33.80
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
76.00
21.70
23.20
14.60
14.84
RevenueValueIndustryS&P 500US Markets
246.17M
18.63
-3.07
-4.98
Earnings HistoryEstimateReportedSurprise %
Q01 20223.193.416.90
Q04 20210.41-0.48-217.07
Q03 2021-0.44-0.432.27
Q02 20210.210.2728.57
Q01 20210.20-0.03-115.00
Q04 2020-1.420.60142.25
Q03 20200.020.512.45K
Q02 2020-0.32-0.0293.75
Earnings Per EndEstimateRevision %Trend
6/2022 QR2.48-18.95Negative
9/2022 QR1.287.56Positive
12/2022 FY8.220.00-
12/2023 FY2.9579.88Positive
Next Report Date8th Aug 2022
Estimated EPS Next Report2.48
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume113.61K
Shares Outstanding13.21K
Shares Float6.64M
Trades Count2.95K
Dollar Volume4.99M
Avg. Volume156.73K
Avg. Weekly Volume184.05K
Avg. Monthly Volume150.75K
Avg. Quarterly Volume135.38K

Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) stock closed at 43.73 per share at the end of the most recent trading day (a 3.19% change compared to the prior day closing price) with a volume of 113.61K shares and market capitalization of 577.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 108 people. Eagle Pharmaceuticals Inc. CEO is Scott L. Tarriff.

The one-year performance of Eagle Pharmaceuticals Inc. stock is -3.94%, while year-to-date (YTD) performance is -14.12%. EGRX stock has a five-year performance of -45.74%. Its 52-week range is between 41.01 and 58.25, which gives EGRX stock a 52-week price range ratio of 15.78%

Eagle Pharmaceuticals Inc. currently has a PE ratio of 15.20, a price-to-book (PB) ratio of 2.59, a price-to-sale (PS) ratio of 2.35, a price to cashflow ratio of 487.90, a PEG ratio of 2.32, a ROA of 12.68%, a ROC of 15.50% and a ROE of 18.09%. The company’s profit margin is 14.84%, its EBITDA margin is 23.20%, and its revenue ttm is $246.17 Million , which makes it $18.63 revenue per share.

Of the last four earnings reports from Eagle Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $2.48 for the next earnings report. Eagle Pharmaceuticals Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Eagle Pharmaceuticals Inc. is Moderate Buy (2.33), with a target price of $48.5, which is +10.91% compared to the current price. The earnings rating for Eagle Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eagle Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eagle Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.61, ATR14 : 1.92, CCI20 : -77.53, Chaikin Money Flow : 0.00, MACD : -1.00, Money Flow Index : 37.21, ROC : -10.59, RSI : 41.43, STOCH (14,3) : 18.05, STOCH RSI : 0.67, UO : 39.62, Williams %R : -81.95), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eagle Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
1 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (25.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
2 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
2.25

Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.

CEO: Scott L. Tarriff

Telephone: +1 201 326-5300

Address: 50 Tice Boulevard, Woodcliff Lake 07677, NJ, US

Number of employees: 108

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

59%41%

Bearish Bullish

58%42%

News

Stocktwits